Chemical biology and experimental therapeutics

Leader of the research programme:

  • Associate Professor Marián Hajdúch, MD., PhD. 
  • Petr Džubák, MD., PhD.

The Program will provide high throughput (HTS) screening on a broad diversity of assays and detection platforms (e.g., enzymes/proteases, G-protein coupled receptors, kinases, cytotoxicity, antiviral, antibacterial, antifungal, protein-protein interactions, protein misfolding/degradation, high-content screening, transcription/expression, etc.). A comprehensive program will be responsible for all operational stages in the lead generation pipeline; assay development, modification and validation, optimization of chemical structure of potent and selective hit compounds identified by HTS, and interactive chemistry to optimize a drug development lead. Hit identification provide assay adaptation/implementation, HTS, and informatics to accept assays into the Program, and then modify and implement them for automated HTS of both BIOMEDREG-generated compounds and custom-made or commercial libraries of compounds. After screening data have been processed and loaded into our database, compounds will be prioritized for re-supply to confirm the hits and for further characterization. As in other academic screening centers, we anticipate re-supplying a maximum of 0.3% of the total number of compounds screened. All quality control, primary, and reconfirmational data will be analyzed by the informatics facility and immediately loaded into the BIOMEDREG Program database.

To optimize hit, information, assay implementation, informatics, and chemistry facilities will cooperate through successive rounds of testing of new compounds to improve the potency and selectivity of the original hits.

Deliverables: 1. Assay methods: Validated HTS screening protocols for individual biological activities; 2. Selection of Hits: List of hits selected from the primary screen using a threshold based on statistical criteria; 3. Validated hits resynthesized or repurchased and retested; 4. Clinical drug candidates. Deliverables will be published in the form of papers, research reports, patents and conference presentations.

Key methodological approaches: High throughput screening of biological activities, genomics, proteomics, metabolomics, bioanalytics, in vivo analysis of biological activities of compounds